Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 ...Middle East

PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor receptor...

Hence then, the article about taiho oncology and cullinan therapeutics present data on zipalertinib in patients with nsclc with egfr mutations and active brain metastases at the esmo congress 2025 was published today ( Monday 13/10/2025 - 01:39 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 )

Also on site :

• I Thought My Marriage Was Happy. Then My Wife Asked Me to Agree to Something I’d Never Imagined.
• Why Now? The Lost Chances to Reach a Hostage Deal, and a Cease-Fire, Months Ago
• SA vs BAN Dream11 Prediction, Dream11 Playing XI, Today Match 14, ICC Women's Cricket World Cup 2025